Moderna Stock Jumps After FDA Advisors Recommend Booster Shot

14 Oct 2021

Moderna Stock Jumps After FDA Advisors Recommend Booster Shot

By Sam — On Thursday, an FDA advisory panel voted unanimously to give booster shots of Moderna 's (NASDAQ:MRNA)  Covid-19 vaccine to people aged 65 and older and other vulnerable citizens. The non-binding decision got 19 yes votes after a two-day meeting based on whether available data on Moderna's Covid-19 vaccine booster supports a booster at least six  months after being vaccinated.The FDA’s Vaccines and Related Biological Products Advisory Committee has brought Moderna's booster shot in line with Pfizer (NYSE:PFE) and BioNTech’s vaccine, which was authorized for the same group less than a month ago.As the approval has come from an advisory committee, the FDA doesn't have to follow its advice. However, it often does, and a final decision from the FDA could arrive in the next few days. A CDC advisory panel would then vote on the FDA's recommendation. Moderna's stock price jumped over 4% after news of the panel's approval. It closed Thursday's session at $331.88, climbing 3.23% from Wednesday.

Facebook Comments

You can comment on Moderna Stock Jumps After FDA Advisors Recommend Booster Shot using Facebook here

Disqus Comments

Join the discussion on Moderna Stock Jumps After FDA Advisors Recommend Booster Shot using Disqus